Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies

Francis Worden, MD, and Hyunseok Kang, MD, express caution regarding the use of liquid biopsies due to discordant findings and the potential lack of tumor shedding compared to other solid tumors, while also warning about the misinterpretation of Clonal hematopoiesis of indeterminate potential mutations.

EP: 1.Differentiated Thyroid Cancer: Examining Key Epidemiological Trends

EP: 2.Exploring Incidence and Histology of Differentiated Thyroid Cancer

EP: 3.Determining Prognosis for Patients with Differentiated Thyroid Cancer

EP: 4.Predisposition for Patients Developing DTC: Age and Gender

EP: 5.The Role of Molecular Diagnostics in Real-World DTC Management

Now Viewing

EP: 6.Employing Liquid Biopsies and ctDNA in DTC Diagnostic Strategies

EP: 7.The Importance of Thyroidectomy in DTC Patient Care

EP: 8.Post-Thyroidectomy Management: Thyroid Hormone Replacement and TSH Suppression

EP: 9.Identifying RAI-Refractory Disease: A Key Aspect of DTC Management

EP: 10.SELECT Trial & DECISION Trial Outcomes and Lessons Learned

EP: 11.Determining Which DTC Patients May Benefit from Systemic Therapy

EP: 12.Exploring Real-World Evidence Presented at ATA 2023

EP: 13.Understanding the Impact of COSMIC-311 and Sequencing in DTC

EP: 14.Toxicity Profiles for DTC Guidelines Therapies

EP: 15.Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment

EP: 16.Neoadjuvant Approach in RAI-R-DTC

EP: 17.Phase 2 ATLEP Trial Results

EP: 18.Reflecting on Differentiated Thyroid Cancer: Final Insights

Related Videos

Related Content

Advertisement

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Related Content

Advertisement

September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment